BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has announced it will release its fourth quarter and full year 2024 financial results on March 25, 2025.
The financial results will be accessible through a press release in the Investors section of BiomX's website. The company plans to host a conference call and audio webcast at a later date, which will coincide with the announcement of initial topline results from its Phase 2 trial investigating treatments for subjects with diabetic foot osteomyelitis.
BiomX Inc. (NYSE American: PHGE), un'azienda in fase clinica focalizzata sullo sviluppo di terapie a base di fagi naturali e ingegnerizzati mirati a specifiche batteri patogeni, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 il 25 marzo 2025.
I risultati finanziari saranno accessibili tramite un comunicato stampa nella sezione Investitori del sito web di BiomX. L'azienda prevede di ospitare una conferenza telefonica e un webcast audio in una data successiva, che coinciderà con l'annuncio dei risultati preliminari della sua sperimentazione di Fase 2 che indaga trattamenti per soggetti con osteomielite del piede diabetico.
BiomX Inc. (NYSE American: PHGE), una empresa en etapa clínica centrada en el desarrollo de terapias con fagos naturales y diseñados que apuntan a bacterias patógenas específicas, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 25 de marzo de 2025.
Los resultados financieros estarán disponibles a través de un comunicado de prensa en la sección de Inversores del sitio web de BiomX. La empresa planea realizar una conferencia telefónica y una transmisión de audio en una fecha posterior, que coincidirá con el anuncio de los resultados preliminares de su ensayo de Fase 2 que investiga tratamientos para sujetos con osteomielitis del pie diabético.
BiomX Inc. (NYSE American: PHGE)는 특정 병원성 박테리아를 겨냥한 자연 및 엔지니어링 파지 치료법 개발에 초점을 맞춘 임상 단계 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 3월 25일에 발표할 것이라고 발표했습니다.
재무 결과는 BiomX 웹사이트의 투자자 섹션에서 보도 자료를 통해 접근할 수 있습니다. 이 회사는 나중에 제2상 시험의 초기 주요 결과 발표와 일치하는 전화 회의 및 오디오 웹캐스트를 개최할 계획입니다. 이 시험은 당뇨병성 발 뼈염 환자에 대한 치료법을 조사하고 있습니다.
BiomX Inc. (NYSE American: PHGE), une entreprise en phase clinique axée sur le développement de thérapies à base de phages naturels et conçus pour cibler des bactéries pathogènes spécifiques, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le 25 mars 2025.
Les résultats financiers seront accessibles via un communiqué de presse dans la section Investisseurs du site Web de BiomX. L'entreprise prévoit d'organiser une conférence téléphonique et un webinaire audio à une date ultérieure, qui coïncidera avec l'annonce des résultats préliminaires de son essai de Phase 2 portant sur des traitements pour des sujets atteints d'ostéomyélite du pied diabétique.
BiomX Inc. (NYSE American: PHGE), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von natürlichen und konstruierten Phagentherapien zur Bekämpfung spezifischer pathogener Bakterien konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 am 25. März 2025 veröffentlichen wird.
Die Finanzergebnisse werden über eine Pressemitteilung im Investorenbereich der BiomX-Website zugänglich sein. Das Unternehmen plant, zu einem späteren Zeitpunkt eine Telefonkonferenz und einen Audio-Webcast abzuhalten, die mit der Bekanntgabe der ersten vorläufigen Ergebnisse seiner Phase-2-Studie zur Untersuchung von Behandlungen für Patienten mit diabetischer Fußosteomyelitis zusammenfallen werden.
- Upcoming Phase 2 trial topline results for diabetic foot osteomyelitis treatment
- None.
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.
A press release reporting the results will be available in the Investors section of the Company’s website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for subjects with diabetic foot osteomyelitis.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
benc@biomx.com
CORE IR
Mike Mason
ir-biomx@biomx.com
FAQ
When will BiomX (PHGE) release its Q4 and full year 2024 financial results?
What clinical trial results will BiomX (PHGE) announce alongside its financial results?
Where can investors access BiomX's (PHGE) Q4 2024 financial results?
What type of therapies is BiomX (PHGE) developing?
